New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting

R Rondanin, G Lettini, P Oliva, R Baruchello, C Costantini, C Trapella, D Simoni, T Bernardi, L Sisinni, M Pietrafesa, G Ponterini, M P Costi, T Vignudelli, R Luciani, D S Matassa, F Esposito, M Landriscina

Research output: Contribution to journalArticlepeer-review

Abstract

TRAP1 (Hsp75) is the mitochondrial paralog of the Hsp90 molecular chaperone family. Due to structural similarity among Hsp90 chaperones, a potential strategy to induce apoptosis through mitochondrial TRAP1 ATPase inhibition has been envisaged and a series of compounds has been developed by binding the simple pharmacophoric core of known Hsp90 inhibitors with various appendages bearing a permanent cationic head, or a basic group highly ionizable at physiologic pH. Cationic appendages were selected as vehicles to deliver drugs to mitochondria. Indeed, masses of new derivatives were evidenced to accumulate in the mitochondrial fraction from colon carcinoma cells and a compound in the series, with a guanidine appendage, demonstrated good activity in inhibiting recombinant TRAP1 ATPase and cell growth and in inducing apoptotic cell death in colon carcinoma cells.

Original languageEnglish
Pages (from-to)2289-2293
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume28
Issue number13
DOIs
Publication statusPublished - Jul 15 2018

Fingerprint Dive into the research topics of 'New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting'. Together they form a unique fingerprint.

Cite this